1. DAVID C. CROSBY, PH.D. San Francisco, CA 94116
415.823.5456 • david.crosby.msl@gmail.com • LinkedIn
Highly motivated medical science liaison interested in exciting medical communications opportunities in
oncology, infectious disease, immunology, or cardiology. Demonstrated ability to engage healthcare
professionals in high-level scientific communication at international infectious disease conferences.
Experienced with profiling national and regional opinion leaders and with building tools and resources
for growing medical affairs business units. Provided competitive intelligence and distilled medical
information from conferences for internal commercial and clinical functions. Nine years of
communications experience as an infectious disease research scientist at both the University of California,
Irvine and UC San Francisco.
PROFESSIONAL EXPERIENCE
Melinta Therapeutics, New Haven, CT (Contracted via The Medical Affairs Company) 2014 - present
Medical Science Liaison, Infectious Disease Western US Territory
As a founding member of Melinta’s field medical affairs team, I identified, profiled, and engaged skin
and skin structure and gonococcal infection opinion leaders in CA, OR, WA, NV, CO, AZ, NM, and ID in
order to bolster Melinta’s relationships with the healthcare community.
• Engaged KOLs at advisory board meetings in an effort to understand how delafloxacin and
Melinta’s preclinical pipeline can best navigate the complex regulatory, commercial, and clinical
challenges unique to antibiotics.
• Represented Melinta medical affairs at international scientific meetings (ICAAC and IDweek),
engaging both KOLs and the heathcare community at large in detailed scientific discussion about
the potential clinical utility of delafloxacin.
• Worked with Melinta marketing to gather key competitive scientific intelligence both at
conferences and from scientific literature important for the commercialization of delafloxacin and
for future development of preclinical candidates.
• Created KOL profiling tools and medical information slide decks (disease state, drug-specific,
current medical practice guidelines, etc.) to be used as cornerstone resources for Meltina’s
growing medical affairs business unit.
University of California, San Francisco (UCSF)., San Francisco, CA 2011 - 2014
Lead Virologist, HIV Accessory and Regulatory Complexes Center (HARC) for the Mission Bay Campus
Assembled and lead interdisciplinary teams of scientists to tackle major unmet biomedical questions
pertaining to the intersection of human immunology and HIV infection.
 Initiated and managed collaborative research stemming from HARC-initiated proteomic surveys.
 Authored several publications detailing novel HIV biology in top-tier, peer-reviewed journals.
 Presented complex scientific findings to diverse audiences at laboratory meetings and
international research conferences.
 Productive collaborations with UCSF investigators including Charly Craik, Ph.D., John Gross,
Ph.D., and Nevan Krogan, Ph.D.
 Mentored/trained visiting postdoctoral researchers, graduate students, undergraduate
volunteers, and research technicians.
University of California, San Francisco (UCSF)., San Francisco, CA 2011 - 2014
Postdoctoral Research Scientist, Alan D. Frankel, Ph.D. Laboratory
Designed, executed, and communicated research investigating the mechanisms of retroviral RNA
metabolism within immune cells.
 Designed and executed dozens of novel scientific experiments exploring HIV RNA metabolism.
 Extensive knowledge and analysis of relevant scientific and clinical literature.
 Frequently interpreted and communicated complex scientific information at laboratory meetings
and international research conferences.

2. PROFESSIONAL EXPERIENCE ( CONT I NU ED)
Advanced Genetic Systems, Inc., San Francisco, CA 2011 - 2014
Virology Consultant for AGS Founder and CEO, Robert Nakamura, Ph.D.
Provided key scientific advice to empower detailed virologic studies of putative inhibitors of HIV Rev
and Tat proteins.
 Designed and developed assays essential to drug characterization in an infectious context.
 Initiated studies and gathered data critical to the success of several SBIR grants.
 Communicated key scientific data to medicinal chemist collaborators at UCSF.
University of California, Irvine, Irvine, CA 2005 - 2011
Graduate Student Researcher – HIV Drug Discovery and Development
Discovered and developed compounds targeting HIV integrase potent against drug-resistant HIV.
 Presented scientific data at international research conferences.
 Extensive training in data and literature critical analysis.
 Taught several undergraduate courses as a teaching assistant.
 Published several high-quality research articles in peer-reviewed journals.
Genentech, Inc., South San Francisco, CA 2003 - 2005
Senior Analyst, Quality Control Stability
Managed product expiry studies for Genentech’s growth hormone line of products (Protropin, Nutropin,
and Nutropin AQ) under FDA 21 CFR, cGMP regulation.
 Managed and performed cGMP-compliant experiments to determine product shelf life.
 Validated standard operating procedures (SOPs) determine product photo- and cryo-stability.
 Trained junior analysts in assay and analysis SOPs.
Cygnus, Inc., Redwood City, CA 2002 - 2003
Senior Analyst, Quality Control Stability
Managed product expiry studies for the GlucoWatch G2 Biographer under 21 CFR regulation.
 Performed cGMP-compliant analyses to determine product shelf life and sterility.
 Designed and validated assays to determine product sterility.
Santa Cruz Biotechnology, Inc., Santa Cruz, CA 1999 - 2001
Research Assistant, Peptide Synthesis
 Produced and characterized synthetic peptides for use as immunogens for antibody generation.
EDUCATION & AFFILIATIONS
Doctorate of Philosophy (Ph.D.), Experimental Pathology, 2010
University of California, Irvine – Department of Pathology, Irvine, CA
Bachelor of Arts (B.A.) – Molecular, Cellular and Developmental Biology, 2002
University of California, Santa Cruz, CA
Bachelor of Arts (B.A.) – Music, 2002
University of California, Santa Cruz, CA
CONTINUING EDUCATION
 UCSF/Burrill & Company-Sponsored “Idea to IPO” Course on Bioentrepreneurship, 2013
 UCSF PharmChem 152 “Drug Discovery and Development” Instructed by Brian Shoichet, 2013
 UCSF Scientific Leadership & Management Skills: A Course for Postdocs & Junior Faculty, 2013
David C. Crosby, Ph.D. Page 2 of 4

3. PROFESSIONAL AFFILIATIONS
 American Society for Microbiology (ASM), 2005-present
 American Association for the Advancement of Science (AAAS), 2005-present
OTHER INTERESTS
• President, Delta Omega Chi Fraternity at UC Santa Cruz, 1998-2001
• Founding member of the UCSC Inter Greek Council and the Delta Omega Chi Alumni
Association gaining 501(c)(3) California non-profit status in 2005.
• Landscape photography, piano and electronic music composition
SELECTED PUBLICATIONS
Jayaraman, B., Crosby, D. C., Homer, C., Ribeiro, I., Mavor, D., and A. D. Frankel, RNA-directed
remodeling of the HIV-1 Rev protein orchestrates assembly of the Rev-Rev response element complex, In
Press, eLife, December 2014.
 Determined the functional relevance of novel Rev-RNA interactions as observed in the solved
Rev dimer-HIV RNA structure on virus replication and RNA metabolism in infected cells.
Crosby, D. C., Lei, X., Gibbs, C. Reinecke, M. G., and W. E. Robinson, Jr., Mutagenesis of lysines 156 and
159 in human immunodeficiency virus type 1 integrase (IN) reveals differential interactions between
these residues and different IN inhibitors. In press, Natural Product Communications, July 2014.
 Designed and characterized the potencies of novel hybrid inhibitors targeting HIV IN against
mutant recombinant IN in biochemical assays and HIV containing mutant IN in virologic assays.
Kim, D. Y.*, Kwon, E.,* Hartley, P. D.,* Crosby, D. C., Mann, S., Krogan, N. J.,* and J. D. Gross* CBFβ
stabilizes HIV Vif to promote APOBEC3 ubiquitination at the expense of RUNX1 mediated gene
expression. Mol. Cell. 2013 Feb 21;49(4) *These authors contributed equally.
 Determined the impact of HIV Vif interactions with host cellular CBFβ on virus replication and
host cellular gene expression at RUNX1 loci.
Stanley D. J.*, Bartholomeeusen, K.*, Crosby, D. C., Kim, D. Y., Kwon, E., Yen, L., Cartozo, N. C., Li, N.,
Jäger, S., Mason-Herr, J., Hayashi, F., Yokoyama, S., Krogan, N. J., Harris, R. S., Peterlin B. M., and J. D.
Gross. Inhibition of a NEDD8 cascade restores restriction of HIV by APOBEC3G. PLoS Pathog. 2012
Dec;8(12). *These authors contributed equally.
 Determined the impact of host cellular UBE2F, UBE2M, RBX1, and RBX2 depletion on virus
replication in T-cells in tissue culture.
Chow, B.T., Soto, M., Lo, B. L., Crosby, D. C. and D. Camerini. Antibacterial activity of four novel
human beta-defensins: HBD-19, HBD-23, HBD-27, and HBD-29. Polymers 2012, 4(1), 747-758
 Designed, expressed, and purified several recombinant human beta-defensin proteins.
Crosby, D. C., Lei, X., Gibbs, C. G., McDougall, B. R., Robinson Jr., W. E., and M. G. Reinecke. Design,
synthesis, and biological evaluation of novel hybrid dicaffeoyltartaric/diketo acid and tetrazole-substituted
L-chicoric acid analog inhibitors of human immunodeficiency virus type 1 integrase. Journal
of Medicinal Chemistry. 2010, 53 (22), pp 8161–8175
 Designed and characterized inhibitors targeting HIV IN in biochemical and virologic assays.
David C. Crosby, Ph.D. Page 3 of 4

4. SELECTED PRESENTATIONS
Jayaraman, B., Crosby, D. C., Homer, C., Ribeiro, I., Mavor, D., and A. D. Frankel, Structural biology of a
HIV-1 Rev-RRE complex. Poster presentation at the 2014 NIH Structural Biology Related to HIV/AIDS
Meeting.
Fernandes, J. D., Crosby, D.C, Faust, T. B., Nakamura, R., Strauli, N., Hernandez, R. D., and A. D.
Frankel, The selfish evolution of two overlapping HIV-1 genes. Poster presentation at the 2014 NIH
Structural Biology Related to HIV/AIDS Meeting.
Crosby, D. C., and A. D. Frankel, An exciting year in the HARC virology core. Oral presentation on
September 27th, 2012, UCSF HARC Center Minisymposium
Crosby, D. C., and A. D. Frankel, HIV-1 Rev oligomerization and viral replication. Oral presentation on
October 24th, 2011, UCSF HARC Center Minisymposium
Crosby, D. C., and W. E. Robinson Jr. Mutations in human immunodeficiency virus type 1 integrase
improve upon viral replication and enzyme catalytic defects conferred by a Q148A mutation within
integrase plus enhance resistance to integrase inhibitors. Poster presentation on March 15th, 2010, Palm
Springs Symposium on HIV/AIDS
Crosby, D. C., and W. E. Robinson Jr. Mutations outside the HIV-1 integrase active site enhance
resistance to the diketo acid integrase inhibitor, XLI-161-1, and elvitegravir. Oral presentation on March
14th, 2009, Palm Springs Symposium on HIV/AIDS
Crosby, D. C., and W. E. Robinson Jr. Mapping of a human immunodeficiency virus type 1 integrase
inhibitor binding pocket, Poster presentation on March 15th, 2008, Palm Springs Symposium on
HIV/AIDS
David C. Crosby, Ph.D. Page 4 of 4